Use este identificador para citar ou linkar para este item: http://repo.saocamilo-sp.br:8080/jspui/handle/123456789/2035
Título: Route of oxytocin administration for preventing blood loss at caesarean section: a systematic review with meta-analysis
Autor(es): Torloni, Maria Regina
Siaulys, Monica
Riera, Rachel
Martimbianco, Ana Luiza Cabrera
Pacheco, Rafael Leite
Latorraca, Carolina de Oliveira Cruz
Widmer, Mariana
Betran, Ana Pilar
Palavras-chave: Efeitos colaterais e reações adversas relacionados a medicamentos
Terapêutica
Cirurgia geral
Data do documento: 2021
Editor: BMJ
Citação: Torloni, Maria Regina, et al. “Route of oxytocin administration for preventing blood loss at caesarean section: a systematic review with meta-analysis”. BMJ Open, vol. 11, no 9, setembro de 2021, p. e051793. DOI.org (Crossref), https://doi.org/10.1136/bmjopen-2021-051793.
Resumo: Objectives: Assess the effects of different routes of prophylactic oxytocin administration for preventing blood loss at caesarean section (CS). Design: Systematic review and meta-analysis. Methods: Medline, EMBASE, CINAHL, Cochrane Library, BVS, SciELO and Global Index Medicus were searched through 24 May 2020 for randomised controlled trials (RCTs) comparing different routes of prophylactic oxytocin administration during CS. Study selection, data extraction and quality assessment were conducted by two investigators independently. We pooled results in fixed effects meta-analyses and calculated average risk ratio (RR), mean difference (MD) and 95% CI. We used GRADE to assess the overall quality of evidence for each outcome. Results: Three trials (180 women) were included in the review. All studies compared intramyometrial (IMY) versus intravenous oxytocin in women having prelabour CS. IMY compared with intravenous oxytocin administration may result in little or no difference in the incidence of postpartum haemorrhage (RR 0.14, 95% CI 0.01 to 2.70; N=100 participants; 1 RCT), hypotension (RR 1.00, 95% CI 0.29 to 3.45; N=40; 1 RCT), headache (RR 3.00, 95% CI 0.13 to 69.52; N=40; 1 RCT) or facial flushing (RR 0.50, 95% CI 0.05 to 5.08; N=40; 1 RCT); IMY oxytocin may reduce nausea/vomiting (RR 0.13, 95% CI 0.02 to 0.69; N=140; 2 RCTs). We are very uncertain about the effect IMY versus intravenous oxytocin on the need for additional uterotonics (RR 0.82; 95% CI 0.25 to 2.69; N=140; 2 RCTs). IMY oxytocin may reduce blood loss slightly (MD -57.40 mL, 95% CI -101.71 to -13.09; N=40; 1 RCT). Conclusions: There is limited, low to very low certainty evidence on the effects of IMY versus intravenous oxytocin at CS for preventing blood loss. The evidence is insufficient to support choosing one route over another. More trials, including studies that assess intramuscular oxytocin administration, are needed on this relevant question.
URI: http://repo.saocamilo-sp.br:8080/jspui/handle/123456789/2035
ISSN: 2044-6055
Aparece nas coleções:Artigos de Periódicos

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.